Teva bids $57.5m for BioXcel dexmedetomidine film in bankruptcy sale
Teva Pharmaceutical Industries has placed a stalking-horse bid of $57.5 million to acquire BXCL501, a dexmedetomidine sublingual film being developed for at-home treatment of acute agitation in adults with schizophrenia or bipolar I or II disorder. The bid is lodged through a court-supervised auction under Section 363 of the US Bankruptcy Code, as BioXcel Therapeutics, the current owner, proceeds through Chapter 11 insolvency proceedings.
The asset is under active FDA review, with a Prescription Drug User Fee Act target action date set for 14 November 2026. If approved in the at-home setting, Teva says it could be the first FDA-cleared outpatient treatment specifically indicated for acute agitation in this patient population. The acquisition does not extend to BioXcel Therapeutics as a corporate entity.
Deal structure
Beyond the $57.5 million upfront payment, Teva could pay up to a further $67.5 million in contingent consideration. Those milestone payments are split between time-based payments linked to the pace and timing of FDA approval and sales-based milestones to be triggered once the product, if approved, reaches specified commercial thresholds. Teva would receive worldwide rights to the dexmedetomidine sublingual film asset under the proposed terms.
As stalking-horse bidder, Teva's proposal establishes the floor for the auction. Other parties may submit higher bids, and the transaction requires approval from the bankruptcy court before it can close. Should Teva be outbid, it is entitled to a break-up fee and expense reimbursement under the terms agreed with BioXcel.
Evan Lippman, Teva's Executive Vice President for Business Development, said the opportunity "strengthens our neuroscience portfolio and reflects our disciplined approach to pursuing innovative assets with a clear strategic fit, the potential to make a meaningful difference for patients and attractive long-term growth potential."
Market context
The acquisition attempt sits within a broader competitive landscape for acute agitation treatments in psychiatric settings. IGALMI, the branded version of dexmedetomidine sublingual film, received FDA approval in 2022 for use under healthcare-provider supervision in clinical settings. The regulatory question now before the agency is whether the safety and dosing profile supports extension to unsupervised, at-home use, a meaningfully different risk threshold given the drug's known cardiovascular side-effect profile, including hypotension and bradycardia.
Teva is not the only large pharmaceuticals group with a strategic interest in psychiatry assets. Competitors including Otsuka, Intra-Cellular Therapies and AbbVie have all strengthened their CNS and psychiatric portfolios in recent years, either through internal development or acquisition. For Teva, the neuroscience franchise, which includes migraine treatment AJOVY and the CGRP portfolio, represents one of the cleaner growth vectors in a business still managing a heavy generics base and significant legacy debt.
The bankruptcy route to acquiring BXCL501 carries execution risk beyond standard M&A. Competing bids could raise the final price, court timelines may extend the uncertainty window ahead of the November PDUFA date, and an FDA decision arriving before deal close could materially shift the asset's value in either direction. Investors will be watching the auction outcome and the FDA's review conclusions as closely linked catalysts.